Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Jury clears J&J of liability in California talc cancer case

A California jury cleared J&J of liability in a case involving a woman who alleged that the company’s talc-based products – including its baby powder – contain asbestos and caused her cancer.

Read More »

Ribometrix Launches With $30 Million to Develop RNA Structure-Based Drugs

Durham, North Carolina-based Ribometrix closed on a Series A financing worth $30 million, led by M Ventures.

Read More »

Sobi buys rights to AstraZeneca infant drug

AstraZeneca took another step to refocus on priority drugs by selling U.S. rights to Synagis for infant lung infections to Swedish Orphan Biovitrum for an upfront fee of $1.5 billion.

Read More »

Nestle raises stake in food allergy drug developer

Nestle’s health science arm will pay $98 million to raise its stake in Aimmune Therapeutics in preparation of submitting a marketing application for the peanut allergy drug AR101 by year-end 2018.

Read More »

AstraZeneca Q3 2018 drug sales turn corner

Strong demand for AstraZeneca’s new drugs – especially those for cancer – drove a return to sales growth in third-quarter 2018 and the drugmaker anticipates years of sustained improvement and rising profit margins.

Read More »

Health stocks up on U.S. vote, insurers hit records

Healthcare stocks rallied with U.S. health insurers reaching record highs as results of the 2018 mid-term elections were seen reducing the likelihood of action to cut medical costs and programs in the world’s biggest and most profitable market.

Read More »

AstraZeneca Sells Asthma and Rhinitis Drugs to Covis

As AstraZeneca focuses on a strategy of divesting assets and spending on the product pipeline, the biopharmaceutical company sold rights to three older drugs to Covis Pharma for $350 million.

Read More »

Illumina to buy rival Pacific Biosciences

Gene sequencing company Illumina Inc. plans to buy Pacific Biosciences of California Inc. in an all-cash deal valued at $1.2 billion.

Read More »

Sanofi and Denali Reach Potential $1+ Billion Deal

Denali announced a collaborative deal with Sanofi to develop potential treatments for neurological and systemic inflammatory diseases that could be worth more than $1 billion.

Read More »

Akoya Biosciences Acquires Phenoptics Portfolio from PerkinElmer

Akoya Biosciences Inc., a Telegraph Hill Partners company, acquired PerkinElmer Inc.’s Phenoptics portfolio.

Read More »

Novartis Cuts 20 Percent of Research Programs

Novartis is abandoning approximately 20 percent of the company’s research projects after a strategic review.

Read More »

AstraZeneca Divests Two Drugs to Grünenthal

Grünenthal will pay AstraZeneca $700 million up-front for the prescription drug rights to the acid-reflux medicine Nexium. AstraZeneca may also receive future milestones and sales-related payments of up to $90 million.

Read More »

Eli Lilly, Dicerna Reach RNAi Therapies Deal

Dicerna Pharmaceuticals and Eli Lilly struck a deal to use an RNAi technology platform for up to 10 cardio-metabolic, neurodegeneration and pain targets.

Read More »

Novartis, Pfizer join forces on potentially lucrative fatty liver disease

Novartis AG and Pfizer Inc. are teaming up to develop treatments for a liver disease tied to obesity and diabetes epidemics that many drug companies believe will become a hugely lucrative market.

Read More »

Abbott, AbbVie settle TriCor marketing case for $25 million

Abbott and AbbVie will pay $25 million to resolve allegations that Abbott paid kickbacks to doctors for prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.

Read More »

Lundbeck Schizophrenia Drug Fails Phase III Study

Lundbeck’s shares plunged after announcing the new drug candidate Lu AF35700 for treatment-resistant schizophrenia failed to differentiate itself against conventional therapies in Phase III.

Read More »

India’s Dr. Reddy’s Q2 profit surges nearly 70 percent

Indian drugmaker Dr. Reddy’s Laboratories posted a 69.7 percent jump in fiscal second-quarter 2018 profit, helped by new product launches.

Read More »

Ultragenyx Plunges With Phase III Trial Failure

Ultragenyx shares were down after announcing the Phase III drug candidate UX007 failed to hit the mark as a treatment for patients with glucose transporter type-1 deficiency syndrome (Glut1 DS) who are experiencing disabling paroxysmal movement disorders.

Read More »

AstraZeneca digs deeper into cancer with Innate stake

AstraZeneca is plowing deeper into cancer immunotherapy through a wide-ranging deal with Innate Pharma, which includes the British group buying a 9.8 percent stake in the French biotech company.

Read More »

Biogen, UCB’s Lupus Treatment Fails Phase II Study

Cambridge, Mass.-based Biogen and Brussels, Belgium-based UCB’s Phase IIb trial of dapirolizumab pegol in lupus failed to hit the primary endpoint, however, the study did show some efficacy and met other secondary endpoints.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2018 Focus: Top 50 Pharma, Company of the Year and more!

Subscribe

Ad Right Bottom